Inventor

Dale B. Schenk

Inventor

Burlingame, CA, US

Overview

1988–2021

Patent span

Human necessities

Primary field (CPC A)

Patents· 73 as inventor

Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.

C07Kprimary

C07KPeptides29%

A61KPreparations for medical, dental or toiletry purposes24%

G01NInvestigating or analysing materials by determining their chemical or physical properties16%

A61PSpecific therapeutic activity of chemical compounds or medicinal preparations12%

Y10STechnical subjects covered by former uspc cross-reference art collections [xracs] and digests7%

Y10TTechnical subjects covered by former us classification4%

C12NMicroorganisms or enzymes3%

A01KAnimal husbandry3%

C12YEnzymes0%

G06FElectric digital data processing0%

PatentTitleYear

11,038,851Tokenizing network appliance and method2021 9,067,981'Hybrid amyloid-beta antibodies'2015 9,051,363'Humanized antibodies that recognize beta amyloid peptide'2015 9,034,337'Treatment and delay of outset of synucleinopathic and amyloidogenic disease'2015 8,791,243'Treatment and prophylaxis of amyloidosis'2014 8,741,298'APOE immunotherapy'2014 8,697,082'Prevention and treatment of synucleinopathic and amyloidogenic disease'2014 8,642,044'Prevention and treatment of amyloidogenic disease'2014 8,636,981'Detection of amyloid deposits using anti-amyloid antibodies'2014 8,535,673'Prevention and treatment of amyloidogenic disease'2013 8,506,959'Prevention and treatment of synucleinopathic and amyloidogenic disease'2013 8,404,815'Chimeric, humanized, or human antibody 2A4'2013 8,268,973'Anti-amyloid antibodies'2012 8,147,833'Prevention and treatment of synucleinopathic and amyloidogenic disease'2012 8,124,081'Prevention and treatment of amyloidogenic diseases'2012 8,092,801'Prevention and treatment of synucleinopathic and amyloidogenic disease'2012 8,034,339'Prevention and treatment of amyloidogenic disease'2011 8,034,348'Prevention and treatment of amyloidogenic disease'2011 7,993,627'Methods for determining whether a compound alters the amount of at least one Î±Î² (X-41) peptide and the amount of either total Î±Î² or at least one Î±Î² (X-40) peptide produced by a non-human mammal'2011 7,977,316'Prevention and treatment of amyloidogenic diseases'2011 7,964,192'Prevention and treatment of amyloidgenic disease'2011 7,928,203'Chimeric, humanized, or human antibody 2A4'2011 7,919,088'Treatment and delay of onset of synucleinopathic and amyloidogenic disease'2011 7,893,214'Humanized antibodies that recognize beta amyloid peptide'2011 7,811,769'Methods for aiding in the diagnosis of Alzheimer\'s disease by measuring amyloid-Î² peptide (x-â‰§41) and tau'2010 7,790,856'Humanized antibodies that recognize beta amyloid peptide'2010 7,727,957'Treatment and delay of outset of Parkinson\'s disease'2010 7,700,751'Humanized antibodies that recognize Î²-amyloid peptide'2010 7,588,766'Treatment of amyloidogenic disease'2009 7,575,880'Method of screening an antibody for activity in clearing an amyloid deposit'2009 7,427,392'Methods for aiding in the diagnosis of alzheimer\'s disease by measuring amyloid-Î² peptide (x-â‰§41) and tau'2008 7,186,881'Testing compounds for effects on synaptophysin in transgenic mice expressing an Alzheimer\'s disease FAD DNA sequence'2007 7,014,855'Prevention and treatment of amyloidogenic disease'2006 6,982,084'Prevention and treatment of amyloidogenic disease'2006 6,972,127'Prevention and treatment of amyloidogenic disease'2005 6,962,707'Prevention and treatment of amyloidogenic disease'2005 6,946,135'Prevention and treatment of amyloidogenic disease'2005 6,936,246'Passive immunization of ASCR for prion disorders'2005 6,923,964'Active immunization of AScr for prion disorders'2005 6,913,745'Passive immunization of Alzheimer\'s disease'2005 6,905,686'Active immunization for treatment of alzheimer\'s disease'2005 6,890,535'Pharmaceutical compositions and methods for treatment of amyloid diseases'2005 6,875,434'Methods of treatment of Alzheimer\'s disease'2005 6,866,850'Prevention and treatment of amyloidogenic disease'2005 6,866,849'Prevention and treatment of amyloidogenic disease'2005 6,818,218'Prevention and treatment of amyloidogenic disease'2004 6,808,712'Prevention and treatment of amyloidogenic disease'2004 6,787,138'Prevention and treatment of amyloidogenic disease'2004 6,787,144'Prevention and treatment of amyloidogenic disease'2004 6,787,523'Prevention and treatment of amyloidogenic disease'2004 6,787,140'Prevention and treatment of amyloidogenic disease'2004 6,787,637'N-Terminal amyloid- antibodies'2004 6,787,139'Prevention and treatment of amyloidogenic disease'2004 6,787,143'Prevention and treatment of amyloidogenic disease'2004 6,761,888'Passive immunization treatment of Alzheimer\'s disease'2004 6,750,324'Humanized and chimeric N-terminal amyloid beta-antibodies'2004 6,743,427'Prevention and treatment of amyloidogenic disease'2004 6,717,031'Method for selecting a transgenic mouse model of alzheimer\'s disease'2004 6,710,226'Transgenic mouse assay to determine the effect of A antibodies and A Fragments on alzheimer\'s disease characteristics'2004 6,610,493'Screening compounds for the ability to alter the production of amyloid- peptide'2003 6,287,793'Diagnostic methods for alzheimer\'s disease'2001 6,284,221'Method for identifying .beta.-amyloid peptide production inhibitors'2001 6,114,133'Methods for aiding in the diagnosis of Alzheimer\'s disease by measuring amyloid-.beta. peptide (x-.gtoreq.41)'2000 6,018,024'Methods and compositions for monitoring cellular processing of beta-amyloid precursor protein'2000 5,837,672'Methods and compositions for the detection of soluble .beta.-amyloid peptide'1998 5,721,130'Antibodies and fragments thereof which bind the carboxyl-terminus of an amino-terminal fragment of .beta.APP'1998 5,605,811'Methods and compositions for monitoring cellular processing of beta-amyloid precursor protein'1997 5,604,102'Methods of screening for .beta.-amyloid peptide production inhibitors'1997 5,593,846'Methods for the detection of soluble .beta.-amyloid peptide'1997 5,512,455'Atrial natriuretic peptide receptor protein'1996 5,441,870'Methods for monitoring cellular processing of .beta.-amyloid precursor protein'1995 5,422,244'Detection of brain .alpha.1-antichymotrypsin'1995 4,745,055'Fused protein for enzyme immunoassay system'1988

Career & activity timeline

Assembled from patent assignee/location history and declaration credentials.

1988–1996Based in Campbell, CA, US· patent location history

1995–2003Patents assigned to ATHENA NEUROSCIENCES INC (7)· patent assignee history

1995–2010Based in Pacifica, CA, US· patent location history

2000–2011Patents assigned to ELAN PHARM INC (11)· patent assignee history

2003–2015Based in Burlingame, CA, US· patent location history

2004–2006Patents assigned to NEURALAB LTD (26)· patent assignee history

2010–2014Patents assigned to JANSSEN ALZHEIMER IMMUNOTHERAP (9)· patent assignee history

2012–2015Patents assigned to SCHENK DALE B (15)· patent assignee history

2014Based in Hillsborough, CA, US· patent location history

2021Based in Acton, CA· patent location history

Inventor activity

Assignee and location history derived from the patent record.

Assignees

Assignee	Patents	Span
NEURALAB LTD	26	2004–2006
SCHENK DALE Bself	15	2012–2015
ELAN PHARM INC	11	2000–2011
JANSSEN ALZHEIMER IMMUNOTHERAP	9	2010–2014
ATHENA NEUROSCIENCES INC	7	1995–2003

Locations

Location	Patents	Span
Burlingame, California, US	55	2003–2015
Pacifica, California, US	13	1995–2010
Campbell, California, US	2	1988–1996
Acton, CA	1	2021
Hillsborough, California, US	1	2014